-
Signature
-
/s/ Charles Carter
-
Stock symbol
-
CERO
-
Transactions as of
-
Feb 14, 2024
-
Transactions value $
-
$0
-
Form type
-
3
-
Date filed
-
2/16/2024, 07:28 PM
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
holding |
CERO |
Series A Convertible Preferred Stock |
|
|
|
|
|
|
Feb 14, 2024 |
Common Stock |
5K |
$10.00 |
Direct |
F1 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Explanation of Responses:
Remarks:
Exhibit 24 - Power of Attorney. Effective immediately after the Effective Time as defined in that certain Business Combination Agreement dated as of June 4, 2023, as amended, by and among the Issuer (f/k/a Phoenix Biotech Acquisition Corp.), CERo Therapeutics, Inc. and PBCE Merger Sub, Inc., the reporting person became an executive officer of the Issuer.